Business Wire

NY-PVH/TOMMY-HILFIGER

14.7.2022 09:02:07 CEST | Business Wire | Press release

Share
Tommy Hilfiger Returns to New York Fashion Week

Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], announces its return to New York Fashion Week for the first time in three years with an experiential runway event that will unveil the latest “See Now, Buy Now” Fall 2022 collection while immersing audiences physically and digitally into a refreshed brand world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005034/en/

Taking place on September 11th at 7 p.m. EDT, the interactive experience draws inspiration from New York’s one-of-a-kind creative scene: an epicenter of people and subcultures, a collision of lo-fi and hi-tech, and a fusion of style and creativity. Infused with the ambiance and raw grit of New York City – the birthplace of the TOMMY HILFIGER brand – the event will connect people through spontaneous moments of creativity at an IRL showcase set at the Skyline Drive-In in Brooklyn and in a parallel metaverse activation.

“My heart immediately went to New York’s iconic creative culture when I thought about where to launch our return to fashion week,” said Tommy Hilfiger. “This is where fashion, art, music and entertainment was all coming together when I first started out in the industry. And today, it is still this approach that inspires me to engage with the cutting-edge communities building new creative experiences. This season is all about the collision of my favorite archival inspirations with new live event concepts and virtual worlds. It’s the perfect expression of what we stand for as we pay homage to our roots with a return to NYFW.”

Innovative multi-media brand activations will bring the Fall 2022 TOMMY HILFIGER collection to life – from New York City to European capitals to Chengdu, and beyond. New retail concepts in select TOMMY HILFIGER stores and takeovers with key wholesale and pure player partners worldwide will complement the phygital showcase. Partnerships with global talent will debut on and off the runway, heroing TOMMY HILFIGER’s roots in shaking up prep classics.

In an industry-first, the “See Now, Buy Now” catwalk will be live-streamed into the global Roblox community of over 50 million daily users, accompanied by avatars dressed in Fall 2022 TOMMY HILFIGER styles who will take over the remixed virtual city of New York. Every style hitting the physical runway will be available to purchase globally through Tommy Hilfiger’s “See Now, Buy Now” concept, including digital product exclusives on Roblox. The brand’s partnership with the global multiverse platform launched in December 2021 and continues to expand through new phases.

Join the conversation on social media using #TommyHilfiger and @TommyHilfiger.

About TOMMY HILFIGER
TOMMY HILFIGER is one of the world’s most recognized premium lifestyle brands, uplifting and inspiring consumers since 1985. The brand creates iconic style, which comes alive at the intersection of the classic and the new, co-created with people who are shaping culture around the world. TOMMY HILFIGER celebrates the essence of classic American style with a modern twist. Tommy Hilfiger offers premium quality and value to consumers worldwide under the TOMMY HILFIGER and TOMMY JEANS lifestyles, with a breadth of collections including men’s, women’s and kids’ sportswear, denim, accessories, and footwear. Tommy Hilfiger has an unwavering commitment to sustainability and inclusivity.

Global retail sales of TOMMY HILFIGER products were approximately $9.3 billion in 2021 and the brand is powered by more than 16,000 associates worldwide — present in 100 countries and more than 2,000 retail stores, including its largest global flagship store at tommy. com. PVH acquired Tommy Hilfiger in 2010 and continues to oversee a focused approach to growing the brand’s worldwide relevance, presence, and long term growth.

About PVH Corp.
PVH is the growth platform for Calvin Klein and TOMMY HILFIGER . Through driving brand strength and relevance, we are connecting our global, iconic brands closer to where the consumer is going than ever before, today and with future generations. Guided by our values and enabled by our scale and global reach, we are driving fashion forward for good, as one team with one vision and one plan. That’s the Power of Us, that’s the Power of PVH+.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 09:00:00 CEST | Press release

New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therape

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release

Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro

Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release

Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO

Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 08:00:00 CEST | Press release

Collaboration combines carrier-grade LoRaWAN® connectivity with award-winning smart street lighting technology to accelerate smart city transformation Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize cri

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye